170 related articles for article (PubMed ID: 25975377)
1. Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers.
Ichimura K; Narita Y; Hawkins CE
Acta Neuropathol; 2015 Jun; 129(6):789-808. PubMed ID: 25975377
[TBL] [Abstract][Full Text] [Related]
2. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.
Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C
Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667
[TBL] [Abstract][Full Text] [Related]
3. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
Korshunov A; Meyer J; Capper D; Christians A; Remke M; Witt H; Pfister S; von Deimling A; Hartmann C
Acta Neuropathol; 2009 Sep; 118(3):401-5. PubMed ID: 19543740
[TBL] [Abstract][Full Text] [Related]
4. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
5. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetics of gliomas.
Appin CL; Brat DJ
Cancer J; 2014; 20(1):66-72. PubMed ID: 24445767
[TBL] [Abstract][Full Text] [Related]
7. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance.
Thota B; Shukla SK; Srividya MR; Shwetha SD; Arivazhagan A; Thennarasu K; Chickabasaviah YT; Hegde AS; Chandramouli BA; Somasundaram K; Santosh V
Am J Clin Pathol; 2012 Aug; 138(2):177-84. PubMed ID: 22904127
[TBL] [Abstract][Full Text] [Related]
8. Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation.
Mott RT; Turner KC; Bigner DD; McLendon RE
J Neurosurg; 2008 Feb; 108(2):330-5. PubMed ID: 18240930
[TBL] [Abstract][Full Text] [Related]
9. Pathology and Genetics of Gliomas.
Komori T; Muragaki Y; Chernov MF
Prog Neurol Surg; 2018; 31():1-37. PubMed ID: 29393190
[TBL] [Abstract][Full Text] [Related]
10. Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics.
Velázquez Vega JE; Brat DJ
Adv Anat Pathol; 2018 May; 25(3):143-171. PubMed ID: 29521646
[TBL] [Abstract][Full Text] [Related]
11. DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome.
Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Pierscianek D; Kim YH; Mariani L; Vital A; Ohgaki H
J Neuropathol Exp Neurol; 2012 Aug; 71(8):702-7. PubMed ID: 22805772
[TBL] [Abstract][Full Text] [Related]
12. Genetic alterations associated with the evolution and progression of astrocytic brain tumours.
Ohgaki H; Schäuble B; zur Hausen A; von Ammon K; Kleihues P
Virchows Arch; 1995; 427(2):113-8. PubMed ID: 7582239
[TBL] [Abstract][Full Text] [Related]
13. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathogenesis of pediatric astrocytic tumors.
Nakamura M; Shimada K; Ishida E; Higuchi T; Nakase H; Sakaki T; Konishi N
Neuro Oncol; 2007 Apr; 9(2):113-23. PubMed ID: 17327574
[TBL] [Abstract][Full Text] [Related]
15. [Gemistocytic astrocytomas].
Matsko DE; Zrelov AA; Ulitin AY; Matsko MV; Skliar SS; Baksheeva AO; Imyanitov EN
Arkh Patol; 2018; 80(4):27-38. PubMed ID: 30059069
[TBL] [Abstract][Full Text] [Related]
16. Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers.
Figarella-Branger D; Maues de Paula A; Colin C; Bouvier C
Rev Neurol (Paris); 2011 Oct; 167(10):683-90. PubMed ID: 21889777
[TBL] [Abstract][Full Text] [Related]
17. Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts.
Jones DT; Mulholland SA; Pearson DM; Malley DS; Openshaw SW; Lambert SR; Liu L; Bäcklund LM; Ichimura K; Collins VP
Acta Neuropathol; 2011 Jun; 121(6):753-61. PubMed ID: 21327941
[TBL] [Abstract][Full Text] [Related]
18. Expression and Prognostic Value of Oct-4 in Astrocytic Brain Tumors.
Krogh Petersen J; Jensen P; Dahl Sørensen M; Winther Kristensen B
PLoS One; 2016; 11(12):e0169129. PubMed ID: 28030635
[TBL] [Abstract][Full Text] [Related]
19. IDH1 mutation can be present in diffuse astrocytomas and giant cell glioblastomas of young children under 10 years of age.
Ferris SP; Goode B; Joseph NM; Kline CN; Samuel D; Gupta N; Bollen A; Perry A; Mueller S; Solomon DA
Acta Neuropathol; 2016 Jul; 132(1):153-5. PubMed ID: 27161253
[No Abstract] [Full Text] [Related]
20. Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma.
Santosh V; Arivazhagan A; Sreekanthreddy P; Srinivasan H; Thota B; Srividya MR; Vrinda M; Sridevi S; Shailaja BC; Samuel C; Prasanna KV; Thennarasu K; Balasubramaniam A; Chandramouli BA; Hegde AS; Somasundaram K; Kondaiah P; Rao MR
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1399-408. PubMed ID: 20501753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
